Colorectal Cancer Screening Market Report 2026

Colorectal Cancer Screening Market Overview

• Colorectal Cancer Screening market size has reached to $16.56 billion in 2025 • Expected to grow to $22.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: The Aging Population Drives Growth In Colorectal Cancer Screening Demand • Market Trend: Innovative Non-Invasive Stool RNA Tests Improve Early Colorectal Cancer Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Colorectal Cancer Screening Market?

Colorectal cancer screening involves testing to detect early signs of colorectal cancer before symptoms develop. Early detection through screening can identify precancerous polyps or cancer at a more treatable stage, significantly improving outcomes. Screening is recommended for adults starting at age 45 or earlier for those at higher risk. The main types of colorectal cancer screening are stool-based, fecal immunochemical tests (FIT), fecal occult blood tests (FOBT), stool deoxyribonucleic acid (DNA) tests, colonoscopy, and others. Stool-based colorectal cancer screening involves analyzing a stool sample for signs of cancer-related substances or abnormalities, such as blood or DNA mutations, to detect potential colorectal cancer. These screenings are categorized by age groups, such as below 50 years, 50-64 years, and above 65 years. The end users of these tests include hospitals and clinics, clinical laboratories, diagnostic imaging centers, and others.

What Is The Colorectal Cancer Screening Market Growth Forecast?

The colorectal cancer screening market size is expected to see strong growth in the next few years. It will grow to $22.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing screening uptake among younger populations, growing integration of AI in endoscopy procedures, expansion of telehealth-supported screening programs, rising focus on personalized cancer risk assessment, increasing investments in preventive healthcare infrastructure. Major trends in the forecast period include increasing adoption of non-invasive screening tests, rising use of AI-assisted colonoscopy systems, growing demand for home-based stool testing kits, expansion of population-wide screening programs, enhanced focus on early detection and preventive care.

Global Colorectal Cancer Screening Market Segmentation

1) By Type: Stool-Based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool Deoxyribonucleic Acid (DNA) Test, Colonoscopy, Other Types 2) By Age Group: Below 50 Years, 50-64 Years, Above 65 Years 3) By End User: Hospitals And Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Other End-Users Subsegments: 1) By Stool-Based: Stool-Based Tests 2) By Fecal Immunochemical Test (FIT): High-Sensitivity FIT, Low-Sensitivity FIT 3) By Fecal Occult Blood Test (FOBT): Guaiac FOBT, Immunochemical FOBT 4) By Stool Deoxyribonucleic Acid (DNA) Test: Multi-Target Stool DNA Test, Single-Target Stool DNA Test 5) By Colonoscopy: Diagnostic Colonoscopy, Therapeutic Colonoscopy 6) By Other Types: Virtual Colonoscopy, Flexible Sigmoidoscopy, Capsule Endoscopy

What Is The Driver Of The Colorectal Cancer Screening Market?

The increasing aging population is expected to propel the growth of the colorectal cancer screening market going forward. An aging population refers to a demographic trend where the proportion of elderly individuals (typically 65 years and older) increases relative to the working-age population, often due to longer life expectancy and declining birth rates. The aging population is growing due to longer life expectancies and declining birth rates, leading to a higher proportion of older adults in the global population. Colorectal cancer screening is essential for managing the needs of the growing aging population by enabling early detection and preventive measures, which address the elevated cancer risk in older adults and enhance their overall health outcomes. For instance, in January 2024, according to the facts published by the Population Reference Bureau (PRB), a US-based nonprofit research organization, the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase, while their proportion of the total population is anticipated to grow from 17% to 23%. Therefore, the increasing aging population is driving the colorectal cancer screening industry.

Key Players In The Global Colorectal Cancer Screening Market

Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE HealthCare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA

Global Colorectal Cancer Screening Market Trends and Insights

Major companies operating in the colorectal cancer screening market are focusing on developing innovative solutions such as non-invasive multi-target stool ribonucleic acid (RNA) colorectal cancer screening tests to offer an accessible, effective method for early detection of colorectal cancer, improving patient outcomes, and encouraging broader screening participation. Non-invasive multi-target stool RNA colorectal cancer screening tests analyze RNA markers from a stool sample to detect the presence of colorectal cancer or precancerous lesions, offering a non-surgical method for early detection. For instance, in May 2024, Geneoscopy Inc., a US-based life sciences company, announced the U.S. Food and Drug Administration (FDA) approval of ColoSense. This uses RNA biomarkers for a non-invasive, stool-based screening that demonstrated 93% sensitivity for detecting colorectal cancer and 45% sensitivity for advanced adenomas. Its significance lies in its high accuracy, especially in younger populations, and its potential to increase screening rates by offering a less invasive alternative to traditional methods.

What Are Latest Mergers And Acquisitions In The Colorectal Cancer Screening Market?

In November 2023, Geneoscopy Inc., a US-based life sciences company, partnered with Laboratory Corporation (LabCorp) to expand access to Geneoscopy’s noninvasive multi-target stool RNA colorectal cancer screening test. This collaboration aims to improve the early and sensitive detection of colorectal cancer and precancerous lesions, address health disparities, and increase screening rates through LabCorp's wide network of healthcare providers and patients. Laboratory Corporation (LabCorp) is a US-based life science and healthcare company providing colon cancer screening and tests.

Regional Insights

North America was the largest region in the colorectal cancer screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Colorectal Cancer Screening Market?

The colorectal cancer screening market includes revenues earned by entities by providing services such as genetic and molecular testing, patient education and awareness programs, and screening result analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Colorectal Cancer Screening Market Report 2026?

The colorectal cancer screening market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer screening industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.